A randomized phase II trial of ipilimumab and nivolumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNNIFORECAST) (2022) Ahrens M, Escudier B, Haanen J, Gross-Goupil M, Boleti E, Gravis G, Grimm MO, et al. Conference contribution Factors associated with long-term survival after failure a chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory large B-cell lymphomas:a role for allogeneic stem cell transplantation? (2022) Derigs P, Bethge W, Holtick U, Von Tresckow B, Ayuk F, Penack O, Vucinic V, et al. Conference contribution Prophylaxis of bacterial Infections and Pneumocystis jirovecii pneumonia in Female Patients with hematological and oncological Diseases: Updated Guideline of the Working Group on Infections (AGIHO) of the German Society for Hematology and Oncology (DGHO) (2022) Classen AY, Henze L, Von Lilienfeld-Toal M, Maschmeyer G, Sandherr M, Duran GL, Alakel N, et al. Conference contribution Auswirkungen eines verkurzten Dosierungsintervalls von Lanreotid-Autogel (LAN) auf die Tumorwachstumsrate ( TGR) bei Patienten mit fortgeschrittenen Neuroendokrinen Tumoren (NETs) in der prospektiven, einarmigen, Phase 2 Studie CLARINET FORTE (2022) Pape UF, Dromain C, Cwikla JB, Lombard-Bohas C, Borbath I, Shah T, Capdevilla J, et al. Conference contribution 12-month trends in health-related quality of life after hospitalization - comparison of tumor entities (2022) Eichler M, Hornemann B, Hoenig K, Bergelt C, Faller H, Maatouk , Stein B, et al. Conference contribution Immune Checkpoint Co-blockade of CD47 and HLA Class I Receptors to increase CD20 Antibody-mediated Phagocytosis of Lymphoma Cells (2022) Zeller T, Lutz S, Munnich IA, Windisch R, Hilger P, Herold T, Tahiri N, et al. Conference contribution Treatment of patients with advanced urothelial carcinoma in routine care in Germany: initial data from the CARAT-UBC cohort (2022) Goebell P, Mueller L, Boegemann M, Rauh J, Nusch A, Andres-Pons A, Hamm N, et al. Conference contribution Recording of the regional Origin Areas of Patients from the Molecular Tumor Board to Identify the "white Spots" in the Service Area - A joint Initiative of the Bavarian CCC WERA Alliance (2022) Lueke F, Haller F, Utpatel K, Krebs M, Meidenbauer N, Scheiter A, Spörl S, et al. Conference contribution Immunophenotypes and Targets of clonally expanded T Cells in the Bone Marrow of Patients with acquired Aplastic Anemia (2022) Ben Hamza A, Welters C, Bruggemann M, Dietze K, Bullinger L, Brummendorf TH, Winkler T, et al. Conference contribution The CAR-HAMATOTOX for risk stratification of severe infections and for the adjustment of antibacterial prophylaxis prior to CD19-targeted CAR T-cell therapy (2022) Rejeski K, Perez A, Iacoboni G, Penack O, Buecklein , Mougiakakos D, Blumenberg , et al. Conference contribution